Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd in HER2-mutant Advanced Lung Cancer With Asymptomatic Brain Metastases
NCT06250777Phase 2Enrolling by invitation
- Sponsor
- Yonsei University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoint: Intracranial Progression-Free Survival at 12 months. Started Jul 2024; status: enrolling by invitation.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06250777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250777.